98%
921
2 minutes
20
Aim: To evaluate a new plasmid mediated RNA interference (RNAi) system and investigate whether knock-down of bcl-xL by short hairpin RNA (shRNA) can induce apoptosis of human nasopharyngeal carcinoma (NPC) cell line CNE-2Z in vitro.
Methods: The plasmid containing mU6 promoter was subcloned to yield the pmU6 plasmid, recombinant plasmid expressing shRNA targeting bcl-xL gene was designed and constructed, and were co-transfected cells with green fluorescence protein expressing plasmid. Flow cytometry was used to evaluate transfection efficiency, and RT-PCR and Western blot were applied to analyze bcl-xL mRNA and protein levels, respectively.
Results: The shRNA expressed by the recombinant plasmid efficiently suppressed bcl-xL gene expression and induced apoptosis of NPC cells in vitro.
Conclusion: The recombinant plasmid can sufficiently mediate RNAi in CNE-2Z cells, and knock-down of the bcl-xL expression by shRNA significantly induced apoptosis in CNE-2Z cells. The results suggest this new system, mediated RNAi can be used as a tool for the study of gene function and gene therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1745-7254.2005.00529.x | DOI Listing |
The persistent residual tumor cells that survive after chemotherapy are a major cause of treatment failure, but their survival mechanisms remain largely elusive. These cancer cells are typically characterized by a quiescent state with suppressed activity of MYC and MTOR. We observed that the MYC-suppressed persistent triple-negative breast cancer (TNBC) cells are metabolically flexible and can upregulate mitochondrial oxidative phosphorylation (OXPHOS) genes and respiratory function ("OXPHOS-high" cell state) in response to DNA-damaging anthracyclines such as doxorubicin, but not to taxanes.
View Article and Find Full Text PDFStem Cell Res
September 2025
Department of Rheumatology and Immunology, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan, Shandong Province, China. Electronic address:
This study describes the establishment of an induced pluripotent stem cell (iPSC) line derived from a patient harboring two heterozygous JAK3 gene mutations: c.1914G > T and c.1048C > T.
View Article and Find Full Text PDFBiochim Biophys Acta Mol Cell Res
August 2025
Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Dist. Ajmer, Rajasthan 305817, India. Electronic address:
Cancer cells often undergo metabolic reprogramming, typically increasing their uptake and utilization of energy sources like glucose, fatty acids, lactate, glutamine, and pyruvate, while maintaining redox balance. Rather than relying on oxidative phosphorylation, cancer cells preferentially engage glycolysis to convert pyruvate into lactate. This metabolic reprogramming correlates with altered glucose metabolism and dysregulated insulin signalling.
View Article and Find Full Text PDFStem Cell Res
August 2025
Tianjin Key Laboratory for Blood Cell Therapy Technology, Union Stem Cell & Gene Engineering Co., Ltd, Tianjin 300384, China; State Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China; VCANBIO Cell & Gene Engineering Corp., Ltd, Tianjin 300384, China. Electronic address: zhangy
The clinical-grade iPSC line UNIONi001-A is derived from HLA-homozygous (HLAh) umbilical cord blood mononuclear cells (CBMCs) of a healthy Han Chinese male neonate. Cells were reprogrammed using episomal plasmids with OCT3/4, SOX2, KLF4, c-MYC and BCL-XL. The iPSCs exhibited typical pluripotent stem cell morphology, expressed pluripotency markers, maintained a normal karyotype, and could differentiate into three germ layers, making them suitable for cell therapy research and clinical use.
View Article and Find Full Text PDFStem Cell Rev Rep
August 2025
Laboratory for Experimental Transfusion Medicine, Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
In vitro red blood cell (RBC) production offers a promising complement to conventional blood donation, particularly for patients with rare blood types. Previously, we developed imBMEP-A, the first erythroid cell line derived from reticulocyte progenitors, which maintains robust hemoglobin expression and erythroid differentiation in the presence of erythropoietin (EPO) despite its immortalized state. However, clinical translation remains hindered by the inability to scale up production due to impaired in vitro enucleation of RBC progenitor cell lines.
View Article and Find Full Text PDF